Soligenix is a late-stage biopharmaceutical company that develops and commercializes products that treat rare diseases. | NASDAQ: SNGX
www.soligenix.com
www.soligenix.com
Location: United States, New Jersey, Princeton
Total raised: $4.82M
Investors 2
| Date | Name | Website |
| - | Medison Ve... | medisonven... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 19.04.2022 | - | $1.4M | - |
| 09.06.2021 | - | $865K | - |
| 09.03.2021 | - | $865K | - |
| 07.05.2020 | - | $840K | - |
| 18.12.2019 | - | $850K | - |
Mentions in press and media 22
| Date | Title | Description |
| 03.09.2024 | Soligenix Receives European Patent for Improved Production of Synthetic Hypericin | Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develop... |
| 09.08.2024 | Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results | PRINCETON, N.J., Aug. 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unme... |
| 09.07.2024 | Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma | Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J., July 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and ... |
| 25.06.2024 | Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma | HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course PRINCETON, N.J., June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biop... |
| 23.05.2024 | Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split | Most shareholders can vote by calling 1-833-782-7145 PRINCETON, N.J., May 23, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing p... |
| 20.05.2024 | Soligenix Encourages Stockholders to Vote Prior to Annual Meeting | Annual Meeting to be held May 23, 2024 PRINCETON, N.J., May 20, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre... |
| 16.05.2024 | Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice | Published Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J., May 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo... |
| 10.05.2024 | Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results | PRINCETON, N.J., May 10, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unme... |
| 06.05.2024 | Soligenix to Present at Upcoming Conferences | PRINCETON, N.J., May 6, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet... |
| 18.04.2024 | Soligenix Announces Pricing of $4.75 Million Public Offering | PRINCETON, N.J., April 18, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare disea... |
Show more